



## **Athersys to Host Conference Call to Announce Phase I Clinical Trial Results Involving MultiStem(R) for Acute Myocardial Infarction**

### **Administration of Adult Stem Cell Therapy for Heart Attack**

CLEVELAND, Jul 28, 2010 (GlobeNewswire via COMTEX News Network) -- Athersys, Inc. (Nasdaq:ATHX) announced it will host a conference call today at 4:30 PM (Eastern Time) to review the top-line data results of the phase I clinical trial of MultiStem(R), its cell therapy treatment for individuals following AMI (or heart attack).

Gil Van Bokkelen, Chairman and Chief Executive Officer, William (B.J.) Lehmann, President and Chief Operating Officer, and John Harrington, Executive Vice President and Chief Scientific Officer, will host the call. Dr. Marc Penn, M.D., Ph.D., co-principal investigator of this study and Director of Cardiovascular Cell Therapy at the Cleveland Clinic, and Director of the Skirball Laboratory for Cardiovascular Cellular Therapeutics, will also participate in the call.

Investors and other interested parties are invited to listen to the conference call by dialing 800-273-1254 in the U.S. and Canada, 973-638-3440 from abroad, or via a live Internet broadcast on the Company's website at [www.athersys.com](http://www.athersys.com), under the Investor Relations section.

A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM (Eastern Time) on August 11, 2010, at the aforementioned URL, or by dialing 800-642-1687 in the U.S. and Canada, or 706-645-9291 from abroad, and entering access code 90560271.

### About Athersys

Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem(R), a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and inflammatory bowel disease. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE(R)). Athersys has forged several key strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at [www.athersys.com](http://www.athersys.com).

The Athersys, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=4548>

This news release was distributed by GlobeNewswire, [www.globenewswire.com](http://www.globenewswire.com)

SOURCE: Athersys, Inc.

CONTACT: Athersys, Inc.

William (B.J.) Lehmann, J.D., President  
and Chief Operating Officer

(216) 431-9900

[bjlehmann@athersys.com](mailto:bjlehmann@athersys.com)

In-Site Communications

Investor Relations:

Lisa M. Wilson

(917) 543-9932

[lwilson@insitecony.com](mailto:lwilson@insitecony.com)

Pure Communications, Inc.

Media Relations:

Sheryl Seapy  
(949) 903-4750

[Sheryl@purecommunicationsinc.com](mailto:Sheryl@purecommunicationsinc.com)

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX